S&P 500   3,890.65 (-0.29%)
DOW   31,533.47 (+-0.01%)
QQQ   320.90 (-0.83%)
AAPL   126.13 (-1.30%)
MSFT   234.56 (-1.00%)
FB   264.36 (-0.21%)
GOOGL   2,073.18 (+0.17%)
TSLA   706.65 (-1.64%)
AMZN   3,136.11 (-0.32%)
NVDA   544.88 (-1.59%)
BABA   238.00 (-1.53%)
CGC   35.70 (+2.79%)
GE   13.06 (-0.38%)
MU   92.27 (-2.63%)
NIO   44.56 (-10.45%)
AMD   85.36 (-1.19%)
T   28.36 (+0.96%)
F   12.47 (+4.09%)
ACB   11.44 (+3.62%)
DIS   194.92 (-0.03%)
BA   223.89 (-0.22%)
NFLX   551.68 (+0.19%)
BAC   35.65 (-0.39%)
S&P 500   3,890.65 (-0.29%)
DOW   31,533.47 (+-0.01%)
QQQ   320.90 (-0.83%)
AAPL   126.13 (-1.30%)
MSFT   234.56 (-1.00%)
FB   264.36 (-0.21%)
GOOGL   2,073.18 (+0.17%)
TSLA   706.65 (-1.64%)
AMZN   3,136.11 (-0.32%)
NVDA   544.88 (-1.59%)
BABA   238.00 (-1.53%)
CGC   35.70 (+2.79%)
GE   13.06 (-0.38%)
MU   92.27 (-2.63%)
NIO   44.56 (-10.45%)
AMD   85.36 (-1.19%)
T   28.36 (+0.96%)
F   12.47 (+4.09%)
ACB   11.44 (+3.62%)
DIS   194.92 (-0.03%)
BA   223.89 (-0.22%)
NFLX   551.68 (+0.19%)
BAC   35.65 (-0.39%)
S&P 500   3,890.65 (-0.29%)
DOW   31,533.47 (+-0.01%)
QQQ   320.90 (-0.83%)
AAPL   126.13 (-1.30%)
MSFT   234.56 (-1.00%)
FB   264.36 (-0.21%)
GOOGL   2,073.18 (+0.17%)
TSLA   706.65 (-1.64%)
AMZN   3,136.11 (-0.32%)
NVDA   544.88 (-1.59%)
BABA   238.00 (-1.53%)
CGC   35.70 (+2.79%)
GE   13.06 (-0.38%)
MU   92.27 (-2.63%)
NIO   44.56 (-10.45%)
AMD   85.36 (-1.19%)
T   28.36 (+0.96%)
F   12.47 (+4.09%)
ACB   11.44 (+3.62%)
DIS   194.92 (-0.03%)
BA   223.89 (-0.22%)
NFLX   551.68 (+0.19%)
BAC   35.65 (-0.39%)
S&P 500   3,890.65 (-0.29%)
DOW   31,533.47 (+-0.01%)
QQQ   320.90 (-0.83%)
AAPL   126.13 (-1.30%)
MSFT   234.56 (-1.00%)
FB   264.36 (-0.21%)
GOOGL   2,073.18 (+0.17%)
TSLA   706.65 (-1.64%)
AMZN   3,136.11 (-0.32%)
NVDA   544.88 (-1.59%)
BABA   238.00 (-1.53%)
CGC   35.70 (+2.79%)
GE   13.06 (-0.38%)
MU   92.27 (-2.63%)
NIO   44.56 (-10.45%)
AMD   85.36 (-1.19%)
T   28.36 (+0.96%)
F   12.47 (+4.09%)
ACB   11.44 (+3.62%)
DIS   194.92 (-0.03%)
BA   223.89 (-0.22%)
NFLX   551.68 (+0.19%)
BAC   35.65 (-0.39%)
Log in
NASDAQ:GILD

Gilead Sciences Stock Forecast, Price & News

Most-Downgraded Stocks  
$63.07
+0.61 (+0.98 %)
(As of 03/2/2021 12:28 PM ET)
Add
Compare
Today's Range
$62.20
Now: $63.07▼
$63.39
50-Day Range
$61.40
MA: $65.18▼
$68.46
52-Week Range
$56.56
Now: $63.07▼
$85.97
Volume295,688 shs
Average Volume8.87 million shs
Market Capitalization$79.06 billion
P/E Ratio65.02
Dividend Yield4.43%
Beta0.51
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; Roche Holding AG; and Vir Biotechnology, Inc. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences logo

Headlines

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
February 28, 2021 |  benzinga.com
GSK to refocus study of experimental COVID-19 antibody treatment on patients 70 and older
February 25, 2021 |  finance.yahoo.com
Positive news on COVID vaccines weighs against concerns over new variants
February 25, 2021 |  finance.yahoo.com
Gilead's COVID-19 drug to be studied in pregnant women
February 18, 2021 |  finance.yahoo.com
Diodes Sees Composite Rating Climb To 97, Breaking Through Buy Zone
February 18, 2021 |  finance.yahoo.com
Diodes Incorporated Reports Fourth Quarter and Fiscal 2020 Financial Results
February 16, 2021 |  finance.yahoo.com
Gilead Sciences and Wake Forest University School of Divinity Partner to Address HIV Epidemic Through Faith-Based Programming and Community Outreach
February 16, 2021 |  finance.yahoo.com
Shareholders Are Raving About How The Diodes (NASDAQ:DIOD) Share Price Increased 357%
February 16, 2021 |  finance.yahoo.com
Gilead (GILD) & Galapagos Discontinue Development of IPF Drug
February 11, 2021 |  finance.yahoo.com
Two-Third Patients Experienced No CRS/Neurologic Events Up To Three Days After Yescarta, New Data From LBCL Study Shows
February 11, 2021 |  feeds.benzinga.com
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
February 10, 2021 |  finance.yahoo.com
Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program
February 10, 2021 |  fool.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GILD
Previous Symbol
CUSIP37555810
CIK882095
Webwww.gilead.com
Phone650-574-3000
Employees11,800
Year Founded1987

Debt

Debt-to-Equity Ratio1.65
Current Ratio3.25
Quick Ratio3.15

Price-To-Earnings

Trailing P/E Ratio65.02
Forward P/E Ratio8.93
P/E Growth0.67

Sales & Book Value

Annual Sales$22.45 billion
Price / Sales3.52
Cash Flow$7.48 per share
Price / Cash Flow8.43
Book Value$17.90 per share
Price / Book3.52

Profitability

EPS (Most Recent Fiscal Year)$6.14
Net Income$5.39 billion
Net Margins5.48%
Return on Equity37.77%
Return on Assets12.76%

Miscellaneous

Outstanding Shares1,253,528,000
Market Cap$79.06 billion
Next Earnings Date4/29/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

2.75 out of 5 stars

Medical Sector

5th out of 1,966 stocks

Biological Products, Except Diagnostic Industry

1st out of 177 stocks

Analyst Opinion: 4.2Community Rank: 3.3Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
$63.07
+0.61 (+0.98 %)
(As of 03/2/2021 12:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

Is Gilead Sciences a buy right now?

25 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 1 sell rating, 12 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Gilead Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
View analyst ratings for Gilead Sciences or view top-rated stocks.

What stocks does MarketBeat like better than Gilead Sciences?

Wall Street analysts have given Gilead Sciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gilead Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Gilead Sciences.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) announced its quarterly earnings results on Thursday, February, 4th. The biopharmaceutical company reported $2.19 EPS for the quarter, beating the Zacks' consensus estimate of $2.15 by $0.04. Gilead Sciences had a trailing twelve-month return on equity of 37.77% and a net margin of 5.48%.
View Gilead Sciences' earnings history.

How has Gilead Sciences' stock price been impacted by COVID-19 (Coronavirus)?

Gilead Sciences' stock was trading at $73.70 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, GILD shares have decreased by 14.5% and is now trading at $62.98.
View which stocks have been most impacted by COVID-19.

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Thursday, February 4th. Investors of record on Monday, March 15th will be paid a dividend of $0.71 per share on Tuesday, March 30th. This represents a $2.84 dividend on an annualized basis and a yield of 4.51%. The ex-dividend date is Friday, March 12th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.68.
View Gilead Sciences' dividend history.

Is Gilead Sciences a good dividend stock?

Gilead Sciences pays an annual dividend of $2.72 per share and currently has a dividend yield of 4.43%. GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences does not yet have a strock track record of dividend growth. The dividend payout ratio of Gilead Sciences is 44.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.80% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.
View Gilead Sciences' dividend history.

What guidance has Gilead Sciences issued on next quarter's earnings?

Gilead Sciences issued an update on its FY21 earnings guidance on Thursday, February, 4th. The company provided earnings per share guidance of $6.75-7.45 for the period, compared to the Thomson Reuters consensus estimate of $6.90. The company issued revenue guidance of $23.70-25.10 billion, compared to the consensus revenue estimate of $24.49 billion.

What price target have analysts set for GILD?

25 brokers have issued twelve-month price objectives for Gilead Sciences' shares. Their forecasts range from $61.00 to $625.00. On average, they expect Gilead Sciences' share price to reach $96.04 in the next twelve months. This suggests a possible upside of 52.5% from the stock's current price.
View analysts' price targets for Gilead Sciences or view top-rated stocks among Wall Street analysts.

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the following people:
  • Mr. Daniel P. O'Day, Chairman & CEO (Age 57, Pay $10.86M)
  • Mr. Andrew D. Dickinson, Exec. VP & CFO (Age 51, Pay $6.91M) (LinkedIn Profile)
  • Mr. Brett A. Pletcher, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53, Pay $2.14M) (LinkedIn Profile)
  • Ms. Johanna Mercier, Chief Commercial Officer (Age 51, Pay $2.55M) (LinkedIn Profile)
  • Dr. Merdad V. Parsey M.D., Ph.D., Chief Medical Officer (Age 58, Pay $1.12M) (LinkedIn Profile)
  • Ms. Diane E. Wilfong, Sr. VP, Corp. Controller & Chief Accounting Officer (Age 59)
  • Ms. Jyoti K. Mehra, Exec. VP of HR (LinkedIn Profile)
  • Dr. William A. Lee, Exec. VP of Research (Age 66)
  • Dr. Taiyin Yang, Exec. VP of Pharmaceutical Devel. & Manufacturing (Age 67)
  • Dr. Diana Brainard M.D., Sr. VP of HIV & Emerging Viral Infections (Age 50)

What is Daniel O’Day's approval rating as Gilead Sciences' CEO?

107 employees have rated Gilead Sciences CEO Daniel O’Day on Glassdoor.com. Daniel O’Day has an approval rating of 92% among Gilead Sciences' employees. This puts Daniel O’Day in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Gilead Sciences' key competitors?

Some companies that are related to Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS).
View all of GILD's competitors.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gilead Sciences investors own include NVIDIA (NVDA), The Walt Disney (DIS), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), Netflix (NFLX) and Johnson & Johnson (JNJ).

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.87%), Dodge & Cox (1.36%), Northern Trust Corp (1.22%), Bank of New York Mellon Corp (1.10%), California Public Employees Retirement System (0.81%) and UBS Asset Management Americas Inc. (0.72%). Company insiders that own Gilead Sciences stock include Brett A Pletcher, Diane E Wilfong, Gayle E Wilson, Javier Rodriguez, John Francis Cogan, Merdad Parsey, Olsen Per Wold and Richard James Whitley.
View institutional ownership trends for Gilead Sciences.

Which institutional investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, American International Group Inc., Price T Rowe Associates Inc. MD, First Trust Advisors LP, Renaissance Technologies LLC, PGGM Investments, and Sumitomo Mitsui Trust Holdings Inc.. Company insiders that have sold Gilead Sciences company stock in the last year include Brett A Pletcher, Diane E Wilfong, Javier Rodriguez, John Francis Cogan, and Merdad Parsey.
View insider buying and selling activity for Gilead Sciences or view top insider-selling stocks.

Which institutional investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including Dodge & Cox, Amundi Pioneer Asset Management Inc., Cibc World Markets Corp, Morgan Stanley, Federated Hermes Inc., KAMES CAPITAL plc, Assenagon Asset Management S.A., and State of Michigan Retirement System.
View insider buying and selling activity for Gilead Sciences or or view top insider-buying stocks.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $62.98.

How much money does Gilead Sciences make?

Gilead Sciences has a market capitalization of $78.95 billion and generates $22.45 billion in revenue each year. The biopharmaceutical company earns $5.39 billion in net income (profit) each year or $6.14 on an earnings per share basis.

How many employees does Gilead Sciences have?

Gilead Sciences employs 11,800 workers across the globe.

Does Gilead Sciences have any subsidiaries?

The following companies are subsidiares of Gilead Sciences: Arresto BioSciences, Asegua Therapeutics LLC, Bristol-Myers Squibb and Gilead Sciences Limited, CGI Pharmaceuticals, CV Therapeutics, Calistoga Pharmaceuticals, Cell Design Labs, Corus Pharma, Cytopia Pty. Ltd., EpiTherapeutics ApS, Epitherapeutics, Forty Seven, Fosun Pharma Kite Biotechnology Co. Ltd., Gilead Alberta LLC, Gilead Alberta ULC, Gilead Apollo LLC, Gilead Apollo Unlimited Company, Gilead Biopharmaceutics Ireland UC, Gilead Biopharmaceutics US LLC, Gilead Calistoga LLC, Gilead Connecticut Inc., Gilead Holdings LLC, Gilead Ireland Research UC, Gilead Oncology Ireland UC, Gilead Pharmasset LLC, Gilead Sciences (NZ), Gilead Sciences (Shanghai) Consulting Co. Ltd., Gilead Sciences Americas S. de R.L., Gilead Sciences Argentina S.R.L., Gilead Sciences Belgium BVBA, Gilead Sciences Canada Inc., Gilead Sciences Denmark ApS, Gilead Sciences Europe Limited, Gilead Sciences Farmacêutica do Brasil Ltda., Gilead Sciences Finland Oy, Gilead Sciences GesmbH., Gilead Sciences GmbH, Gilead Sciences Hangzhou Pharmaceutical Co. Ltd., Gilead Sciences Hellas EPE, Gilead Sciences Holding LLC, Gilead Sciences Hong Kong Limited, Gilead Sciences India Private Limited, Gilead Sciences International Limited, Gilead Sciences Ireland UC, Gilead Sciences Israel Limited, Gilead Sciences KK, Gilead Sciences Korea Limited, Gilead Sciences LLC, Gilead Sciences Lda., Gilead Sciences Limited, Gilead Sciences Luxembourg S.a.r.l., Gilead Sciences Malaysia Sdn. Bhd., Gilead Sciences Mexico S. de R.L. de C.V., Gilead Sciences Netherlands BV, Gilead Sciences Norway AS, Gilead Sciences Poland Sp. z o.o., Gilead Sciences Pty. Ltd., Gilead Sciences Russia LLC, Gilead Sciences S.L., Gilead Sciences S.r.l., Gilead Sciences SAS, Gilead Sciences Shanghai Pharmaceutical Technology Co. Ltd., Gilead Sciences Singapore Pte. Ltd., Gilead Sciences Slovakia s.r.o., Gilead Sciences South Africa (Pty) Ltd., Gilead Sciences Sweden AB, Gilead Sciences Switzerland Sarl, Gilead Sciences YM Australia Pty. Ltd., Gilead Sciences llac Ticaret Limited Sirketi, Gilead Sciences s.r.o., Gilead Therapeutics A1 Unlimited Company, Gilead Therapeutics A2 Unlimited Company, Gilead YM ULC, Immunomedics, KP EU C.V., Kite Pharma, Kite Pharma EU B.V., Kite Pharma Inc., Kite Pharma LLC, Kite Pharma UK Ltd, MYR, Myogen, NeXstar Pharmaceuticals, Nimbus Apollo, Nycomed, Pharmasset, Phenex Pharmaceuticals, Raylo Chemicals, Tri-Supply Limited, Triangle Pharmaceuticals, YM BioSciences, YM BioSciences Australia Pty. Ltd., and neoKite Inc..

When was Gilead Sciences founded?

Gilead Sciences was founded in 1987.

What is Gilead Sciences' official website?

The official website for Gilead Sciences is www.gilead.com.

Where are Gilead Sciences' headquarters?

Gilead Sciences is headquartered at 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.